Baicalin ameliorates atherosclerosis by inhibiting NLRP3 inflammasome in apolipoprotein E-deficient mice
Diabetes and Vascular Disease Research · 2020-11 · 17 (6)
DOI: 10.1177/1479164120977441 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes and Vascular Disease Research, online erschienen am 03.12.2020. Verfasst von Jingfei Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Third People's Hospital of Liaocheng City, Liaocheng, Shandong, China. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
NLR family pyrin domain containing 3 (NLRP3) inflammasome has been implicated in the development of atherosclerosis and several studies have suggested that inhibiting NLRP3 inflammasome could be a potential therapeutic approach to treat atherosclerosis. Baicalin is a flavone glycoside with anti-inflammation, anti-oxidative activities. The inhibition of NLRP3 inflammasome activation by baicalin has also been described. Therefore, the effects of baicalin on NLRP3 inflammasome activation and atherosclerosis were evaluated in present study.
Methods
We established the apolipoprotein E-deficient atherosclerosis mice model. After baicalin treatment, the IL-1, IL-18, and reactive oxygen species (ROS) production, and the plaque area was monitored. We also measured the NLRP3, ASC, caspase-1, ICAM-1, and VCAM-1 expression in atherosclerosis mice after baicalin treatment. We silenced NLRP3 by administration of lentivirus expressing NLRP3 shRNA to atherosclerosis mice and monitored the IL-1, IL-18, and ROS production, and NLRP3 inflammasome activation.
Results
Baicalin remarkably inhibited the production of IL-1, IL-18, mitochondria ROS, total ROS, ICAM-1, and VCAM-1. Baicalin reduced the expression of NLRP3 inflammasome and suppressed its activation. Baicalin significantly reduced the plaque area. Silencing NLRP3 resulted in decreased production of IL-1, IL-18, mitochondria ROS, total ROS, ICAM-1, and VCAM-1, and inhibition of NLRP3 inflammasome activation.
Conclusion
Baicalin ameliorated atherosclerosis by inhibiting NLRP3 inflammasome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Third People's Hospital of Liaocheng City, Liaocheng, Shandong, China.
- Department of Orthopedic, Third People's Hospital of Liaocheng City, Liaocheng, Shandong, China.
- Department of Vascular Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.
ORCID-Profile: Qingbo Su
Zitieren
APA
Zhao, J., Wang, Z., Yuan, Z., Lv, S., & Su, Q. (2020). Baicalin ameliorates atherosclerosis by inhibiting NLRP3 inflammasome in apolipoprotein E-deficient mice. Diabetes and Vascular Disease Research, 17(6). https://doi.org/10.1177/1479164120977441
Vancouver
Zhao J, Wang Z, Yuan Z, Lv S, Su Q. Baicalin ameliorates atherosclerosis by inhibiting NLRP3 inflammasome in apolipoprotein E-deficient mice. Diabetes and Vascular Disease Research. 2020;17(6). doi:10.1177/1479164120977441
BibTeX
@article{Zhao2020,
author = {Zhao, Jingfei and Wang, Zhengtang and Yuan, Zhilu and Lv, Shuzhen and Su, Qingbo},
title = {Baicalin ameliorates atherosclerosis by inhibiting NLRP3 inflammasome in apolipoprotein E-deficient mice},
journal = {Diabetes and Vascular Disease Research},
year = {2020},
volume = {17},
number = {6},
doi = {10.1177/1479164120977441}
}
EUVIMED